NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

About this update from Neonc Technologies Holdings, Inc.

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended June 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Second Quarter & Recent Corporate Highlights Clinical Pipeline Progress NEO100-01 – Intranasal therapy for malignant gliomas NEO212 – Bio-conjugated therapy for brain cancer NEO100-3 – Pediatric indication trial initiated with patient recruitment underway. Financial Results for Q2 2025 Executive Chairman Commentary Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies Holdings, stated: “This has been a transformative period for NeOnc. Meeting all the outstanding contingencies for our $50 million strategic partnership with Quazar Investment, being added to the Russell Microcap Index, advancing multiple clinical programs, and acquiring cutting-edge AI and quantum modeling capabilities position us for accelerated growth. We believe these developments not only strengthen our clinical and technological platforms but also create a solid foundation for long-term shareholder value creation. Looking ahead, we expect to have fully enrolled both our NEO100-01 and NEO212 trials before end of 3rd Quarter, with FDA readouts anticipated by the end of 2025 and into the beginning of Q1 2026. Our focus remains on delivering life-changing therapies for patients while executing on strategic initiatives that can significantly expand our market opportunity.” Upcoming Catalysts About NeOnc Technologies Holdings, Inc. NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) is a multi–Phase 2 clinical-stage biotechnology company developing novel therapies for brain cancer and other CNS disorders. With a robust intellectual property portfolio, advanced delivery platforms, and collaborations with leading academic centers, NeOnc is committed to transforming outcomes in some of the most difficult-to-treat areas of oncology. “NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc. Company Contact: [email protected] Investor Contact: James Carbonara, Hayden IR – (646) 755-7412 | [email protected]

View stock analysis, news, and events for Neonc Technologies Holdings, Inc.